‘Most Exciting Thing I’ve Seen In My Lifetime’: FDA Panel Approves Groundbreaking Cancer Treatment
Full approval from the agency is expected to follow.
The independent source for health policy research, polling, and news.
32,461 - 32,480 of 112,425 Results
Full approval from the agency is expected to follow.
Experts have warned that the report expected to be released today on the finances of Medicare could launch a process under the health law to make cuts. A panel expected to do that, called the Independent Payment Advisory Board, has not been named, however.
The Government Accountability Office did say the agency could do better at providing clear and transparent information about potential side effects of the experimental drugs. In other pharmaceutical news: the House passed an Food and Drug Administration authorization bill, President Donald Trump considers scaling down a program that makes drugmakers give discounted products to hospitals, and a new method might help shave off development time for drugs.
Brenda Fitzgerald chose to partner with Coke in an effort to fight obesity, a move that raises some eyebrows. “We hope Dr. Fitzgerald, as head of Centers for Disease Control and Prevention, avoids partnering with Coke on obesity for the same reason she would avoid partnering with the tobacco industry on lung cancer prevention,” said Jim O’Hara of the Center for Science in the Public Interest.
The funding boost for the National Institutes of Health, which was advanced by a House subcommittee, is counter to the White House plan to slash medical research spending and is offset with reductions to family planning and refugee services.
Civil rights advocates file suit against California, alleging that care provided by Medi-Cal, the state’s health program for low-income people, is substandard and disproportionately hurts Latinos — by far the largest group of enrollees.
Acting Indian Health Service Director Rear Adm. Michael Weahkee says he visited the hospitals in question and "saw a committed caring workforce that is working hard.”
Although Republicans often point to signs suggesting the individual insurance markets are collapsing, recent analysis suggests they are stabilizing, Politico reports. Other news outlets look at insurance issues including some companies' move to cover early chronic health problems to forestall bigger expenses later and efforts to keep beneficiaries out of emergency rooms.
The ongoing opioid crisis is also expected to be a topic at the National Governors Association's three-day conference.
The uninsured rate among Native Americans would climb by 27.4 percent in Kansas and 36.2 percent in Missouri.
The comments come as the majority leader is scrambling to garner support for his legislation.
Discussions about what to do if the GOP's proposed legislation fails are under way, prompting senators to quietly reach across the aisle.
Sen. Pat Toomey (R-Pa.), a proponent of the reductions, said he has been led to believe that the new draft bill will not change much on the question of Medicaid funding. If so, that could make it hard for some moderate senators to support the measure.
America's Health Insurance Plans, an insurer trade group, warns that the conservative amendment to allow companies to sell skimpy plans would destabilize the market and harm coverage for people with pre-existing conditions.
Republicans say the taxes are killing jobs and strangling economic growth, but paired with their plans for rolling back Medicaid, the cuts may become politically toxic to Republicans.
Sen. Rand Paul (R-Ky.) says he won't vote for the legislation, and Sen. Susan Collins (R-Maine) has also voiced strong opposition to the measure. That means Senate Majority Leader Mitch McConnell (R-Ky.) needs the vote of every single one of the rest of the 50 Republicans to pass the bill. The revised draft will be out today.
Today's early morning highlights from the major news organizations.
Opinion writers offer their analysis of the ongoing debate on Capitol Hill and across the country over health care reforms and issues.
Read recent commentaries about drug-cost issues.
News outlets report on stories related to pharmaceutical pricing.
© 2026 KFF